The Europe generic drug market size reached US$ 56.7 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 89.1 Billion by 2028, exhibiting a growth rate (CAGR) of 7.6% during 2023-2028.
Generic drugs are pharmaceutical drugs with an equivalent therapeutic effect as their branded counterparts. These drugs are also identical to the innovator drug in terms of safety, strength, quality, dosage route of administration and intended usage. Unlike branded drugs, generic drugs are cost-efficient and they do not require hefty investments in marketing campaigns or clinical studies.
Governments of various countries in Europe, along with healthcare authorities, are presently concerned about inflating pharmaceutical prices. As a result, they are increasingly promoting the usage of generic drugs over their branded counterparts, which represents one of the significant factors propelling the growth of the market. Apart from this, low production costs of generic drugs are attracting manufacturers to make capital investments in the industry. Moreover, the rising utilization of 3D printing technology in the healthcare sector is resulting in the increasing launch of generic drugs with customized sizes, forms and textures. Furthermore, the high prevalence of chronic diseases in the region is propelling governing agencies to finance research and development (R&D) for launching new compounds and improving existing technologies.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the Europe generic drug market report, along with forecasts at the regional and country level from 2023-2028. Our report has categorized the market based on segment, therapy area, drug delivery and distribution channel.
Breakup by Segment:
Unbranded Generics
Branded Generics
Breakup by Therapy Area:
Central Nervous System
Cardiovascular
Dermatology
Genitourinary/Hormonal
Respiratory
Rheumatology
Diabetes
Oncology
Others
Breakup by Drug Delivery:
Oral
Injectables
Dermal/Topical
Inhalers
Breakup by Distribution Channel:
Retail
Hospital
Breakup by Country:
Germany
France
United Kingdom
Italy
Spain
Others
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players.
Report Coverage:
Report Features
Details
Base Year of the Analysis
2022
Historical Period
2017-2022
Forecast Period
2023-2028
Units
US$ Billion
Segment Coverage
Segment, Therapy Area, Drug Delivery, Distribution Channel, Country
Countries Covered
Germany, France, United Kingdom, Italy, Spain, Others
Customization Scope
10% Free Customization
Report Price and Purchase Option
Single User License: US$ 2699
Five User License: US$ 3699
Corporate License: US$ 4699
Post-Sale Analyst Support
10-12 Weeks
Delivery Format
PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)
Key Questions Answered in This Report
The Europe generic drug market was valued at US$ 56.7 Billion in 2022.
We expect the Europe generic drug market to exhibit a CAGR of 7.6% during 2023-2028.
The rising prevalence of numerous chronic diseases, such as diabetes, dyslipidemia, hypertension, etc., owing to the sedentary lifestyles, hectic work schedules, and changing dietary patterns of the consumers, is primarily driving the Europe generic drug market.
The sudden outbreak of the COVID-19 pandemic has led to the extensive R&D activities pertaining to launch of generic drugs to combat the spread of the coronavirus infection across several European nations.
Based on the therapy area, the Europe generic drug market can be categorized into central nervous system, cardiovascular, dermatology, genitourinary/hormonal, respiratory, rheumatology, diabetes, oncology, and others. Currently, central nervous system accounts for the majority of the total market share.
Based on the therapy area, the Europe generic drug market can be categorized into central nervous system, cardiovascular, dermatology, genitourinary/hormonal, respiratory, rheumatology, diabetes, oncology, and others. Currently, central nervous system accounts for the majority of the total market share.
Based on the drug delivery, the Europe generic drug market has been segregated into oral, injectables, dermal/topical, and inhalers. Among these, oral currently exhibits a clear dominance in the market.
Based on the distribution channel, the Europe generic drug market can be bifurcated into retail and hospital. Currently, retail holds the largest market share.
On a regional level, the market has been classified into Germany, France, United Kingdom, Italy, Spain, and others.
Need more help?
Speak to our experienced analysts for insights on the current market scenarios.
Include additional segments and countries to customize the report as per your requirement.
Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
For further assistance, please connect with our analysts.
Gain a deeper dive into a specific application, geography, customer, or competitor
Any level of personalization
Get in Touch With Us
UNITED STATES
Phone: +1-631-791-1145
INDIA
Phone: +91-120-433-0800
UNITED KINGDOM
Phone: +44-753-713-2163
Email: sales@imarcgroup.com
Client Testimonials
IMARC made the whole process easy. Everyone I spoke with via email was polite, easy to deal with, kept their promises regarding delivery timelines and were solutions focused. From my first contact, I was grateful for the professionalism shown by the whole IMARC team. I recommend IMARC to all that need timely, affordable information and advice. My experience with IMARC was excellent and I can not fault it.
The IMARC team was very reactive and flexible with regard to our requests. A very good overall experience. We are happy with the work that IMARC has provided, very complete and detailed. It has contributed to our business needs and provided the market visibility that we required
We were very happy with the collaboration between IMARC and Colruyt. Not only were your prices competitive, IMARC was also pretty fast in understanding the scope and our needs for this project. Even though it was not an easy task, performing a market research during the COVID-19 pandemic, you were able to get us the necessary information we needed. The IMARC team was very easy to work with and they showed us that it would go the extra mile if we needed anything extra
We would be happy to reach out to IMARC again, if we need Market Research/Consulting/Consumer Research or any associated service. Overall experience was good, and the data points were quite helpful.
The figures of market study were very close to our assumed figures. The presentation of the study was neat and easy to analyse. The requested details of the study were fulfilled. My overall experience with the IMARC Team was satisfactory.
The overall cost of the services were within our expectations. I was happy to have good communications in a timely manner. It was a great and quick way to have the information I needed.
My questions and concerns were answered in a satisfied way. The costs of the services were within our expectations. My overall experience with the IMARC Team was very good.
I agree the report was timely delivered, meeting the key objectives of the engagement. We had some discussion on the contents, adjustments were made fast and accurate. The response time was minimum in each case. Very good. You have a satisfied customer.
We would be happy to reach out to IMARC for more market reports in the future. The response from the account sales manager was very good. I appreciate the timely follow ups and post purchase support from the team. My overall experience with IMARC was good.
IMARC was a good solution for the data points that we really needed and couldn't find elsewhere. The team was easy to work, quick to respond, and flexible to our customization requests.
This site uses cookies (including third-party cookies) to record user’s preferences which help us to enhance our services. For further information review our Privacy Policy.
This site uses cookies to improve user experience.Privacy Policy.